Indeed, anti-angiogenic agents, either alone or in combination with immune checkpoint inhibitors, may have particular relevance for MTM-HCC patients, a hypothesis supported by the efficacy of VEGF/PD-L1 dual blockade in recent systemic therapy trials [24,25]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.